FDA Issues Warning for EluxadolineAnti-IBS drug Viberzi (eluxadoline) increases risk of severe pancreatitis.
FDA approves eluxadoline to treat IBS-D in adultsFew treatment options are available for irritable bowel syndrome with diarrhea. Eluxadoline acts on the nervous system to lessen bowel contraction.
FDA approves 2 new IBS-D treatmentsThe FDA approved two new treatments to treat irritable bowel syndrome with diarrhea (IBS-D), Viberzi (eluxadoline) and Xifaxan (rifaximin), this week.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations